These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30562905)

  • 1. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative jerk as an outcome measure in nonambulatory Duchenne muscular dystrophy.
    Fujii T; Takeshita E; Iwata Y; Yajima H; Nozaki F; Mori M; Kumada T
    Brain Dev; 2019 Oct; 41(9):796-802. PubMed ID: 31213334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative study to understand the Duchenne muscular dystrophy experience from the parent/patient perspective.
    Brown V; Merikle E; Johnston K; Gooch K; Audhya I; Lowes L
    J Patient Rep Outcomes; 2023 Dec; 7(1):129. PubMed ID: 38085412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy.
    Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K
    Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy.
    Hogrel JY; Decostre V; Ledoux I; de Antonio M; Niks EH; de Groot I; Straub V; Muntoni F; Ricotti V; Voit T; Seferian A; Gidaro T; Servais L
    J Neurol; 2020 Jul; 267(7):2022-2028. PubMed ID: 32206900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W
    Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory capacity in Japanese patients with Duchenne muscular dystrophy.
    Awano H; Itoh C; Takeshima Y; Lee T; Matsumoto M; Kida A; Kaise T; Suzuki T; Matsuo M
    Brain Dev; 2018 Jun; 40(6):465-472. PubMed ID: 29551259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower Extremity Muscle Involvement in the Intermediate and Bethlem Myopathy Forms of COL6-Related Dystrophy and Duchenne Muscular Dystrophy: A Cross-Sectional Study.
    Batra A; Lott DJ; Willcocks R; Forbes SC; Triplett W; Dastgir J; Yun P; Reghan Foley A; Bönnemann CG; Vandenborne K; Walter GA
    J Neuromuscul Dis; 2020; 7(4):407-417. PubMed ID: 32538860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD.
    Duong T; Canbek J; Birkmeier M; Nelson L; Siener C; Fernandez-Fernandez A; Henricson E; McDonald CM; Gordish-Dressman H;
    J Neuromuscul Dis; 2021; 8(6):939-948. PubMed ID: 34151852
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.